United Therapeutics wins FDA nod for third-gen Tyvaso TD-300/A nebulizer

United Therapeutics (NSDQ:UTHR) said today that its third-generation inhalation device designed for use with its Tyvaso treprostinil inhalation solution won FDA approval.
Tyvaso first won FDA approval in 2009 as a treatment for pulmonary arterial hypertension, the company said, with an ultrasonic nebulizer. United Therapeutics touted its drug-device combo as the most-prescribed inhalation therapy for PAD in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post United Therapeutics wins FDA nod for third-gen Tyvaso TD-300/A nebulizer appeared first on MassDevice.

Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat United Therapeutics Source Type: news